← Reviews
Open AccessVollständige AnalyseJun 20, 2026

GABA-producing Lactococcus lactis alleviates gut dysfunction and neurobehavioral abnormalities associated with irritable bowel syndrome

The full text provided contains only a repeated introduction; no experimental data were supplied, making it impossible to determine direction or magnitude of effect.

The question (PICO)
PopulationIndividuals with IBS (subtype not specified in available data)
InterventionGABA-producing Lactococcus lactis (strain, dose and route not reported in provided text)
VergleichNot determinable — experimental data absent from provided text
EndpunktGut dysfunction and neurobehavioral abnormalities — specific metrics not available in provided text
DEvidenz
Studie
Study
Effekt
Unzureichend
Zusammenfassung der Ergebnisse nach Endpunkt
EndpunktGradRichtungEffektStudien
Gut dysfunction (declared primary outcome — no data available)D Unzureichendnot reported
Neurobehavioral abnormalities (declared secondary outcome — no data available)D Unzureichendnot reported
Gut dysfunction (declared primary outcome — no data available)D
Richtung Unzureichend
Effektnot reported
Studien
Neurobehavioral abnormalities (declared secondary outcome — no data available)D
Richtung Unzureichend
Effektnot reported
Studien

Kontext

IBS affects up to 11% of the global population, with the diarrhea-predominant subtype (IBS-D) most prevalent. The gut-brain axis and microbial GABA are emerging therapeutic targets. In situ GABA-producing probiotics bypass the blood-brain barrier permeability limitations of oral GABA.

Was die Studie zeigte

The provided text contains no results section with experimental data. The Methods, Results and Discussion sections are identical to the Introduction. No numerical data, 95% CIs, effect sizes or measured outcomes are available for analysis. Asserting any direction of effect would be unsupported extrapolation.

Wie es durchgeführt wurde

Experimental design, sample size, duration and study population are not described in the provided text. The journal is Microbiome Research Reports (2025), received June 2025, accepted September 2025. Whether the study is preclinical (animal) or clinical cannot be determined.

Effektgröße

Not calculable. No effect data were reported in the provided text.

Einschränkungen

Critical limitation of this analysis: the full text provided replicates the introduction across all three sections, with no primary data. Risk of bias tools (RoB 2 for RCTs, ROBINS-I for observational studies) could not be applied. Internal and external validity of the study are indeterminate.

In der klinischen Praxis

No clinical recommendation can be derived from this text. The theoretical rationale (microbial GABA in IBS) is biologically plausible but unsupported by experimental data in the provided material. Clinicians should await publication of the complete experimental text.

Was noch fehlt

The complete experimental text with actual methods, results and discussion is required. RCTs in humans with IBS-D are needed before any clinical inference about GABA-producing L. lactis can be made.

Quelle: DOI 10.20517/mrr.2025.56 · 2025

Microbiota Weekly

Die Mikrobiota-Evidenz der Woche, in Ihrer Sprache. Strukturierte Zusammenfassungen, rückverfolgbar zur Quelle.